Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer

Han-Sang Baek,Kabsoo shin,Jinyoung Kim,Chaiho Jeong,Jeongmin Lee,Yejee Lim,Ki-Hyun Baek,Jeonghoon Ha

DOI: https://doi.org/10.1007/s00774-024-01552-0

2024-10-01

Journal of Bone and Mineral Metabolism

Abstract:Chemotherapy-induced bone loss (CTIBL) is common among breast cancer patients, requiring comprehensive assessment and intervention. Zoledronic acid, a strong inhibitor of bone resorption, is effective in CTIBL management, though information on dosing and intervals, particularly the efficacy of the 5 mg annual dose for osteoporosis in breast cancer patients, is limited.

endocrinology & metabolism,medicine, research & experimental